• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

April 2, 2018
Company Drug/Device Medical Condition Status
GT Biopharma Inc. GTP-004 myasthenia gravis Phase I trials initiated
LivaNova PLC Perceval sutureless aortic heart valve diseased native or malfunctioning prosthetic aortic valve Phase I trials initiated enrolling 160 subjects in China
Five Prime Therapeutics, Inc. FPA150 B7-H4 expression observed in multiple solid tumors, including breast, bladder and gynecologic cancers Phase I trials initiated
vTv Therapeutics Inc. TTP399 type 1 diabetes Phase Ib trials initiated
Allecra Therapeutics AAI101 complicated urinary tract infections (cUTIs) Phase II trials initiated
Flex Pharma Inc. FLX-787 multiple sclerosis Phase II trials initiated enrolling 57 subjects
Eiger Biopharmaceuticals, Inc. exendin 9-39 post-bariatric hypoglycemia (PBH) Phase II trials initiated enrolling 36 subjects
ProMetic Life Sciences Inc. PBI-4050 Alström syndrome Phase II trials initiated enrolling 12 subjects
MiMedx Group, Inc. AminoFix Injectable Plantar Fasciitis Phase IIb trials initiated enrolling 145 subjects
MiMedx Group, Inc. AminoFix Injectable Osteoarthritis (OA) of the knee Phase IIb trials initiated enrolling 318 subjects
BrainStorm Cell Therapeutics Inc. NurOwn amyotrophic lateral sclerosis (ALS) Phase III trials initiated enrolling subjects from Canada
Urovant Sciences vibegron overactive bladder Phase III trials initiated enrolling 1,400 subjects

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing